Impact Biomedical Inc. (IBO) — SEC Filings
Impact Biomedical Inc. (IBO) — 30 SEC filings. Latest: 144 (Apr 29, 2026). Includes 12 8-K, 6 10-Q, 5 S-1/A.
View Impact Biomedical Inc. on SEC EDGAR
Overview
Impact Biomedical Inc. (IBO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S filed on Apr 6, 2026: Impact Biomedical Inc. filed an S-8 POS form on April 6, 2026, to register securities for its employee benefit plans. This filing indicates the company is making shares available for its employees, likely as part of compensation or incentive programs. The filing itself does not disclose specific dol
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant filing sentiment for Impact Biomedical Inc. is neutral.
Filing Type Overview
Impact Biomedical Inc. (IBO) has filed 2 4, 1 144, 1 S, 6 10-Q, 12 8-K, 1 DEF 14A, 2 10-K, 5 S-1/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of IBO's 24 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $25,000 |
| Net Income | -$17,105,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $12,000 |
| Operating Margin | N/A |
| Total Assets | $18,208,000 |
| Total Debt | $27,061,000 |
Key Executives
- Frank D. Heuszel
- Darrin M. Ocasio, Esq.
- Jason Grady
- Dr. Elise Brownell
- Melissa Sims
- Joseph M. Lucosky, Esq.
Industry Context
The biotechnology sector is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies often rely on substantial funding to advance their pipelines. The current environment may see increased scrutiny on financial viability and revenue generation from early-stage biotech firms.
Top Tags
sec-filing (5) · material-agreement (4) · 10-Q (3) · pharmaceuticals (3) · registration-statement (2) · Biotechnology (2) · Related Party Transactions (2) · Net Loss (2) · 8-K (2) · quarterly-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $17,105,000 | for the nine months ended September 30, 2025, compared to $2,363,000 net income in prior year |
| Cash and Cash Equivalents | $12,000 | as of September 30, 2025, down from $1,999,000 at December 31, 2024 |
| Note Payable, Related Party | $22,881,000 | as of September 30, 2025, up from $8,878,000 at December 31, 2024 |
| Change in Fair Value of Note Payable, Related Party | $13,210,000 | negative impact on income for the nine months ended September 30, 2025 |
| Total Revenue | $25,000 | for the nine months ended September 30, 2025, from biotech retail sales |
| Total Liabilities | $27,061,000 | as of September 30, 2025, up from $13,053,000 at December 31, 2024 |
| Professional Fees | $868,000 | for the nine months ended September 30, 2025, up from $313,000 in prior year |
| Sales, General and Administrative Compensation | $755,000 | for the nine months ended September 30, 2025, up from $424,000 in prior year |
| Audit fees for Grassi & Co. | $60,000 | for fiscal year ended December 31, 2024 |
| Anticipated low-end audit fees for Grassi & Co. | $40,000 | for fiscal year ending December 31, 2025 |
| Anticipated high-end audit fees for Grassi & Co. | $85,000 | for fiscal year ending December 31, 2025 |
| Tax fees for Greendyke, Jencik & Associates CPA’s, PLLC | $2,000 | for fiscal year ended December 31, 2024 |
| Voting shares owned by DSS BioHealth Securities, Inc. | 83.35% | includes 100% of Series A Convertible Preferred Stock |
| Shares of Common Stock outstanding | 12,185,412 | on Record Date September 8, 2025 |
| Shares of Series A Convertible Preferred Stock | 60,496,041 | owned by DSS BioHealth Securities, Inc. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Impact Biomedical Inc. (IBO)?
Impact Biomedical Inc. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 12 8-K, 6 10-Q, 5 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IBO filings?
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Impact Biomedical Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Impact Biomedical Inc. (IBO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Impact Biomedical Inc.?
Key financial highlights from Impact Biomedical Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IBO?
The investment thesis for IBO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Impact Biomedical Inc.?
Key executives identified across Impact Biomedical Inc.'s filings include Frank D. Heuszel, Darrin M. Ocasio, Esq., Jason Grady, Dr. Elise Brownell, Melissa Sims and 1 others.
What are the main risk factors for Impact Biomedical Inc. stock?
Of IBO's 24 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Impact Biomedical Inc.?
Forward guidance and predictions for Impact Biomedical Inc. are extracted from SEC filings as they are enriched.